Major Depressive Disorder Market Size, Share, Industry, and Outlook (2023-2030)

<h2>Major Depressive Disorder Market is segmented By Drug Type (Antidepressants, Atypical Antidepressants, Antipsychotics, Neuromodulators) By Route of Administration (Oral, Intravenous, Parenteral) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)&nbsp;and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

<h3>Market Overview</h3>

<blockquote>
The Global Major Depressive Disorder Market reached US$ YY&nbsp;billion in 2022 and is expected to reach US$ YY&nbsp;million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
</blockquote>

Major depressive disorder (MDD) also referred to as depression, is one of the most severe and common psychiatric disorders across the world. It is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.&nbsp;

MDD is a condition characterized by mood swings, which can be triggered by various factors such as genetics, stress, hormone imbalance, alcohol or drug use, certain medical conditions, specific medications, and childhood abuse. The exact cause is unknown, but these factors can increase the risk of developing MDD.&nbsp;

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Size Available for Years
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2021-2030
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2023-2030
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Data Availability
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Drug Type, Route of Administration, Distribution Channel
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific&nbsp;
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<h3>Market Dynamics: Drivers and Restraints</h3>

Rise in technological advancements in treatment options

Over the past two decades, significant progress has been made in the treatment options for major depressive disorder (MDD). It is now recognized that depression varies from person to person, and efforts are being made to identify and diagnose the specific neurochemical imbalances in individuals to tailor treatment accordingly.&nbsp;

Advances have been made in evidence-based treatments, particularly in drug therapy. More selective and specialized antidepressants, such as citalopram, escitalopram, fluoxetine, and sertraline, have been developed, offering improved efficacy and fewer side effects. Combining drug therapy with psychotherapy, specifically cognitive-behavioral and psychodynamic therapy, has been shown to be the most effective approach.

For instance, Eliem Therapeutics, Inc a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, provided an update on its plans to advance its ETX-155 clinical program.

Furthermore, Work life imbalances due to lifestyle changes, and an increase in the MDD patient pool are the key drivers expected to drive the MDD treatment market over the forecasted period. Partnerships for co-development and co-marketing of MDD drugs among drug manufacturers across the globe, the development of new drugs, and adequate government reimbursement policies have also fueled the growth of the MDD treatment market.

<h3>Restraint</h3>

Major depressive disorder (MDD) can cause more than depression.&nbsp; It can lead to complications that affect your health and change how you think and behave. Some of the complications include weight gain and obesity, chronic illness, chronic pain, self-harm, cognitive changes and others.

However, stringent regulations imposed by various governments for new drug approval, patent expiries of some blockbuster drugs, risk of complications with other medications, and related side effects of major depressive disorder drugs hamper the growth of the major depressive disorder treatment market over the forecasted period.&nbsp;

&nbsp;

For more details on this report &ndash; <a href="https://www.datamintelligence.com/download-sample/major-depressive-disorder-market" target="_blank">Request for Sample</a>

<h2>&nbsp;</h2>

<h3>Segment Analysis</h3>

The global major depressive disorder is segmented based on drug type, route of administration, distribution channel and region.

The Antidepressants from the drug type&nbsp; segment accounted for approximately 41.2 % of the market share&nbsp;

The Antidepressants from the drug type segment accounted for approximately 41.2 % and it is expected to be dominated during the forecast period. Antidepressants are psychiatric drugs which are licensed to treat depression. Some are also licensed to treat other conditions, such as anxiety disorders phobias, bulimia (an eating disorder), and some physical conditions, including managing long-term pain.

For instance, in December 2022 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.

Moreover, in September 2022 Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced positive results from a phase III clinical trial in Japan of brexpiprazole in the treatment of major depressive disorder. The late-stage trial evaluated the efficacy and safety of brexpiprazole as adjunctive therapy in 740 adult patients in Japan, aged 20 to 64 years, with major depressive disorder. Brexpiprazole was administered once daily for six weeks, in 1 mg or 2 mg doses, as an adjunctive therapy to SSRI or SNRI antidepressants, for patients who previously had inadequate responses to antidepressant monotherapy.

<h3>&nbsp;Geographical Analysis</h3>

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to an increase in the number of patients suffering from major depressive disorder, advancement in technology to develop new therapeutic drugs, rise in the ongoing clinical trials, advanced healthcare infrastructure and among others are expected to dominate by this region during the forecast period.

For instance, according to clinicaltrails.gov in September 2022 Janssen Research &amp; Development, LLC started clinical studies on a Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) which is under phase 3 with 840 active participants have been enrolled and these studies have been going in Alabama United states.

Moreover, according to clinicaltrails.gov on November 2022 Otsuka Pharmaceutical Development &amp; Commercialization, Inc started a clinical study on a Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder which is under Phase 3 with 900 enrolled participants and this studies currently going in New York United States.&nbsp;

<h3>COVID-19 Impact Analysis</h3>

COVID-19 had a substantial impact on major depressive disorder where according to studies published on the Impact of the COVID-19 pandemic on major depressive disorder in acute psychiatric inpatients where the studies focused on the relationship between COVID-19 and mental disorders reported results similar to those summarized above about psychiatric symptoms in the general population.&nbsp;

In particular, a large systematic review and meta-analysis found an increase of 27.6% in the prevalence of major depressive disorder (MDD) after the outbreak of the COVID-19 pandemic (COVID-19 Mental Disorders Collaborators, 2021) with a peak of the incidence from March to May 2020 in conjunction with the first restriction measures.&nbsp;

<h3>Competitive Landscape</h3>

The major global players in the major depressive disorder market include Eli Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson &amp; Johnson, Pfizer, Inc, AstraZeneca plc, Merck &amp; Co, GlaxoSmithKline plc, Sanofi S.A and among others.

Key Developments

<ul>
	<li>In September 2023 Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3, long-term, open-label, registrational trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).</li>
	<li>In August 2023&nbsp; Biogen Inc. and Sage Therapeutics, Inc announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD.&nbsp;</li>
	<li>In May 2023 - BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced positive top-line data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film.&nbsp;</li>
</ul>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global major depressive disorder market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development</li>
	<li>Excel data sheet with numerous major depressive disorder market-level data points with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global major depressive disorder market report would provide approximately 69 tables, 70 figures, and 185 Pages.

<h3>Target Audience 2023</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Drug Type</li>
		<li>Snippet by Route of Administration</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Driver
			<ol>
				<li>Rise in technological advancements in treatment options</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Complications associated with the disease</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Russia-Ukraine War Impact Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Drug Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Attractiveness Index, By Drug Type</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Antidepressants*</h3>

		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Atypical Antidepressants</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Antipsychotics</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Neuromodulators</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Route of Administration&nbsp;</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Attractiveness Index, By Route of Administration</li>
		</ol>
		</li>
		<li>Oral*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Intravenous</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Parenteral</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Retail Pharmacies</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Online Pharmacies</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Eli Lilly and Company&nbsp;
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Allergan</li>
		<li>Alkermes</li>
		<li>Lundbeck</li>
		<li>Johnson &amp; Johnson</li>
		<li>Pfizer, Inc</li>
		<li>AstraZeneca plc</li>
		<li>Merck &amp; Co</li>
		<li>GlaxoSmithKline plc</li>
		<li>Sanofi S.A&nbsp;</li>
		<li>Takeda Pharmaceutical Company Limited&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Major Depressive Disorder Market Value, By Drug Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 2 Global Major Depressive Disorder Market Value, By Route of Administration, 2022, 2026 &amp; 2030 (US$ Million)

Table 3 Global Major Depressive Disorder Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 (US$ Million)

Table 4 Global Major Depressive Disorder Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Million)

Table 5 Global Major Depressive Disorder Market Value, By Drug Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 6 Global Major Depressive Disorder Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 7 Global Major Depressive Disorder Market Value, By Route of Administration, 2022, 2026 &amp; 2030 (US$ Million)

Table 8 Global Major Depressive Disorder Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Major Depressive Disorder Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 (US$ Million)

Table 10 Global Major Depressive Disorder Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Major Depressive Disorder Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Million)

Table 12 Global Major Depressive Disorder Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Major Depressive Disorder Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 14 North America Major Depressive Disorder Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Major Depressive Disorder Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Major Depressive Disorder Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Major Depressive Disorder Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 18 South America Major Depressive Disorder Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Major Depressive Disorder Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Major Depressive Disorder Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Major Depressive Disorder Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 22 Europe Major Depressive Disorder Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Major Depressive Disorder Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Major Depressive Disorder Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Major Depressive Disorder Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Major Depressive Disorder Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Major Depressive Disorder Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Major Depressive Disorder Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East &amp; Africa Major Depressive Disorder Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 30 Middle East &amp; Africa Major Depressive Disorder Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East &amp; Africa Major Depressive Disorder Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Eli Lilly and Company: Overview

Table 33 Eli Lilly and Company: Product Portfolio

Table 34 Eli Lilly and Company: Key Developments

Table 35 Allergan: Overview

Table 36 Allergan: Product Portfolio

Table 37 Allergan: Key Developments

Table 38 Alkermes: Overview

Table 39 Alkermes: Product Portfolio

Table 40 Alkermes: Key Developments

Table 41 Lundbeck: Overview

Table 42 Lundbeck: Product Portfolio

Table 43 Lundbeck: Key Developments

Table 44 Johnson &amp; Johnson: Overview

Table 45 Johnson &amp; Johnson: Product Portfolio

Table 46 Johnson &amp; Johnson: Key Developments

Table 47 Pfizer, Inc: Overview

Table 48 Pfizer, Inc: Product Portfolio

Table 49 Pfizer, Inc: Key Developments

Table 50 AstraZeneca plc: Overview

Table 51 AstraZeneca plc: Product Portfolio

Table 52 AstraZeneca plc: Key Developments

Table 53 Merck &amp; Co: Overview

Table 54 Merck &amp; Co: Product Portfolio

Table 55 Merck &amp; Co: Key Developments

Table 56 GlaxoSmithKline plc: Overview

Table 57 GlaxoSmithKline plc: Product Portfolio

Table 58 GlaxoSmithKline plc: Key Developments

Table 59 Sanofi S.A: Overview

Table 60 Sanofi S.A : Product Portfolio

Table 61 Sanofi S.A: Key Developments&nbsp;

List of Figures

Figure 1 Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 2 Global Major Depressive Disorder Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 3 Global Major Depressive Disorder Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 4 Global Major Depressive Disorder Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 5 Global Major Depressive Disorder Market Share, By Region, 2022 &amp; 2030 (%)

Figure 6 Global Major Depressive Disorder Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 7 Antidepressants Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 8 Atypical Antidepressants Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 9 Antipsychotics Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 10 Neuromodulators Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 11 Global Major Depressive Disorder Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 12 Oral Route of Administration&nbsp; in Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 13 Intravenous Route of Administration&nbsp; in Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 14 Parenteral Route of Administration&nbsp; in Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 15 Global Major Depressive Disorder Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 16 Hospital Pharmacies Distribution Channel in Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 17 Retail Pharmacies Distribution Channel in Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 18 Online Pharmacies Distribution Channel in Global Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 19 Global Major Depressive Disorder Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 21 Asia-Pacific Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 22 Europe Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 23 South America Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 24 Middle East and Africa Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 25 North America Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 26 North America Major Depressive Disorder Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 27 North America Major Depressive Disorder Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 28 North America Major Depressive Disorder Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 29 North America Major Depressive Disorder Market Share, By Country, 2022 &amp; 2030 (%)

Figure 30 South America Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 31 South America Major Depressive Disorder Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 32 South America Major Depressive Disorder Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 33 South America Major Depressive Disorder Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 34 South America Major Depressive Disorder Market Share, By Country, 2022 &amp; 2030 (%)

Figure 35 Europe Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 36 Europe Major Depressive Disorder Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 37 Europe Major Depressive Disorder Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 38 Europe Major Depressive Disorder Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 39 Europe Major Depressive Disorder Market Share, By Country, 2022 &amp; 2030 (%)

Figure 40 Asia-Pacific Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 41 Asia-Pacific Major Depressive Disorder Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 42 Asia-Pacific Major Depressive Disorder Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 43 Asia-Pacific Major Depressive Disorder Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 44 Asia-Pacific Major Depressive Disorder Market Share, By Country, 2022 &amp; 2030 (%)

Figure 45 Middle East &amp; Africa Major Depressive Disorder Market Value, 2021-2030 (US$ Million)

Figure 46 Middle East &amp; Africa Major Depressive Disorder Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 47 Middle East &amp; Africa Major Depressive Disorder Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 48 Middle East &amp; Africa Major Depressive Disorder Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 49 Eli Lilly and Company: Financials

Figure 50 Allergan: Financials

Figure 51 Alkermes: Financials

Figure 52 Lundbeck: Financials

Figure 53 Johnson &amp; Johnson: Financials

Figure 54 Pfizer, Inc: Financials

Figure 55 AstraZeneca plc: Financials

Figure 56 Merck &amp; Co: Financials

Figure 57 GlaxoSmithKline plc: Financials

Figure 58 Sanofi S.A: Financials

Major Depressive Disorder Market Size, Share, Industry, and Outlook (2023-2030)

Antidepressant Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 January 16

Starting from